GlassScriptPhysician profile
Julie A Bauer
NPI 1255749719
$7,273.86
in general payments reported to CMS, 2019-2025
28 companies · $2,893 in 2025
The $2,893 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.47 · 2022: $585 · 2023: $2,220 · 2024: $1,519 · 2025: $2,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,561 · Consulting Fee: $1,000 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.56 |
| Consulting Fee | $1,000.00 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,863.82 | 2021-2025 | |
| Janssen Biotech, INC. | $688.98 | 2022-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $679.86 | 2023-2025 | Dupixent, Libtayo |
| Incyte Corporation | $518.00 | 2022-2025 | Opzelura |
| Ucb, INC. | $494.60 | 2023-2025 | Bimzelx |
| Dermavant Sciences, INC. | $437.89 | 2023-2024 | Vtama |
| Leo Pharma INC. | $318.92 | 2023-2025 | Anzupgo, Adbry |
| Lilly USA, LLC | $314.28 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $305.91 | 2022-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $303.75 | 2022-2025 | |
| Amgen INC. | $195.70 | 2025 | Otezla |
| Galderma Laboratories, L.P. | $163.66 | 2022-2025 | Nemluvio |
| Botanix Sb INC | $161.48 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $118.69 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $110.81 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $110.47 | 2025 | Vtama |
| Almirall LLC | $74.34 | 2022-2023 | Klisyri |
| Organogenesis INC. | $73.09 | 2024-2025 | Puraply Wound Matrix, Affinity |
| Arcutis Biotherapeutics, INC. | $62.92 | 2023-2024 | Zoryve |
| Kyowa Kirin, INC. | $47.18 | 2024 | Poteligeo |
| Mayne Pharma Commercial LLC | $45.89 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.18 | 2021 | |
| Pfizer INC. | $32.67 | 2025 | |
| Lnhc, INC | $30.10 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $24.98 | 2025 | Vyjuvek |
| Biowound Solutions, INC. | $23.57 | 2025 | Bio-Connekt |
| Biofrontera INC. | $18.55 | 2025 | Ameluz |
| E.R. Squibb & Sons, L.L.C. | $15.57 | 2025 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.